8-K: BioAffinity Technologies Announces CFO Departure and Appointment of Interim CFO

BioAffinity Technologies' CFO, Michael Dougherty, is resigning to pursue another opportunity, and former CFO, Michael Edwards, will return as interim CFO.

Summary

• Michael Dougherty, the Chief Financial Officer and Principal Accounting Officer of bioAffinity Technologies, Inc., has resigned effective September 16, 2024, to pursue another opportunity.
• Michael Edwards, who previously served as bioAffinity's CFO, has been appointed as the Interim Chief Financial Officer and Principal Accounting Officer, effective September 16, 2024.
• Mr. Edwards will receive a monthly salary of $10,000 plus expenses under a consulting agreement.
• The company has initiated a search for a permanent CFO.
• Mr. Dougherty's resignation was not due to any disagreements with the company's operations, policies, or practices.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there is a CFO departure, the company has a plan in place with an experienced interim CFO and expects a seamless transition. The company also highlights the success of its CyPath Lung test.

Positives

• The transition is expected to be seamless due to the strong financial team and processes in place.
• Michael Edwards has extensive experience with bioAffinity, having served as CFO previously for nine years and leading the company through its IPO.
• The company has a strong financial team and processes in place.
• CyPath Lung has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer.

Negatives

• The departure of the current CFO, Michael Dougherty, may cause some disruption.
• The company will incur additional costs for the interim CFO's salary and expenses.

Risks

• The transition to a new CFO could pose challenges if not managed effectively.
• The company's ability to find a suitable permanent CFO in a timely manner is uncertain.
• There are risks and uncertainties that could cause actual results to differ materially from current expectations.

Future Outlook

The company expects a seamless transition and is initiating a search for a permanent CFO. The company believes the financial team and processes are strong and will ensure the ongoing success of the Finance Department. The company also notes that there are risks and uncertainties that could cause actual results to differ materially from current expectations.

Management Comments

• We expect a seamless transition given the strong team and financial processes that Mike Dougherty has put in place and Michael Edwards extensive experience as bioAffinitys previous CFO, said bioAffinity Technologies President and CEO Maria Zannes.
• Mike has made significant contributions to bioAffinitys success and is leaving us in good hands.
• I am grateful for the opportunity to work for bioAffinity Technologies and support its mission for the early detection of lung cancer, said Dougherty.
• I have every confidence in the team we built and the financial planning and processes we implemented.

Industry Context

The announcement reflects typical executive transitions within the biotechnology sector. The company's focus on non-invasive cancer detection aligns with the broader industry trend towards early diagnosis and personalized medicine.

Comparison to Industry Standards

• The appointment of an interim CFO while searching for a permanent replacement is a common practice in the industry.
• The financial terms of the consulting agreement with the interim CFO appear to be within industry norms for similar roles.
• The company's focus on non-invasive cancer detection aligns with the broader industry trend towards early diagnosis and personalized medicine, similar to companies like Exact Sciences and Guardant Health.
• The reported sensitivity, specificity, and accuracy of CyPath Lung are competitive with other diagnostic tests in the market.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the CFO transition.
• Employees in the finance department will experience a change in leadership.
• Customers and partners may not be significantly impacted by this change.

Next Steps

• The company will initiate a search for a permanent CFO.
• Michael Edwards will serve as interim CFO until a permanent replacement is found.

Key Dates

Keywords

CFO, Chief Financial Officer, Interim CFO, bioAffinity Technologies, Michael Dougherty, Michael Edwards, financial officer, executive change, CyPath Lung, cancer detection